Michael B. Otteneder

1.3k citations

33 papers · 859 indexed · h-index 17

Molecular Biology
Radiology, Nuclear Medicine and Imaging top 10%
Cancer Research top 10%
Oncology
Immunology

Co-authors: Werner K. Lutz Lawrence J. Marnett Sven Kronenberg Björn Jacobsen Annika Herrmann John P. Plastaras Ben‐Fillippo Krippendorff James N. Riggins
Topics: Monoclonal and Polyclonal Antibodies Research (10 papers)Protein purification and stability (8 papers)DNA Repair Mechanisms (6 papers)
Cited by: Cancer Research Radiology, Nuclear Medicine and Imaging Chemical Health and Safety
Journals: Proceedings of the National Academy of Sciences PLoS ONE Analytical Chemistry
Partner nations: Switzerland United States Germany

In The Last Decade

Michael B. Otteneder

33 papers receiving 829 citations

Peers

Countries citing papers authored by Michael B. Otteneder

Since Specialization

Citations

This map shows the geographic impact of Michael B. Otteneder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael B. Otteneder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael B. Otteneder more than expected).

Fields of papers citing papers by Michael B. Otteneder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael B. Otteneder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael B. Otteneder. The network helps show where Michael B. Otteneder may publish in the future.

Co-authorship network of co-authors of Michael B. Otteneder

This figure shows the co-authorship network connecting the top 25 collaborators of Michael B. Otteneder. A scholar is included among the top collaborators of Michael B. Otteneder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael B. Otteneder. Michael B. Otteneder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Innate immune response to AAV-based gene therapy vectors: Mechanisms of complement activation and cytokine release 2025 ·Molecular Therapy — Methods & Clinical Development ·(unknown),Petra Schwalie,Emma Bell,Désirée von Tell,Guido Steiner,(unknown),Julian J. Freen‐van Heeren,Annelies W. Turksma,Richard B. Pouw,Timo Schwandt,Michael B. Otteneder,Theo Rispens,Mieke C. Brouwer,(unknown),Hélène Haegel	1
2	A Brief Review of Radiolabelling Nucleic Acid‐Based Molecules for Tracking and Monitoring 2024 ·Journal of Labelled Compounds and Radiopharmaceuticals ·(unknown),Filippo Sladojevich,Stephen M. Husbands,Michael B. Otteneder,Ian S. Blagbrough	3
3	Investigating brain uptake of a non-targeting monoclonal antibody after intravenous and intracerebroventricular administration 2022 ·Frontiers in Pharmacology ·(unknown),Antje‐Christine Walz,(unknown),(unknown),Thomas E. Kraft,Inja Waldhauer,Michael B. Otteneder	6
4	Pharmacokinetics and Determination of Tumor Interstitial Distribution of a Therapeutic Monoclonal Antibody Using Large-Pore Microdialysis 2021 ·Journal of Pharmaceutical Sciences ·(unknown),Satyawan Jadhav,(unknown),(unknown),Michael Gertz,Michael B. Otteneder,(unknown),Hartmut Derendorf	5
5	“Catch-and-Release” Anti-Carcinoembryonic Antigen Monoclonal Antibody Leads to Greater Plasma and Tumor Exposure in a Mouse Model of Colorectal Cancer 2018 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown),(unknown),(unknown),Bo An,Michael B. Otteneder,Jun Qu,Joseph P. Balthasar	14
6	Quantification of IgG monoclonal antibody clearance in tissues 2017 ·mAbs ·(unknown),(unknown),Hans Peter Grimm,Michael B. Otteneder,Ben‐Fillippo Krippendorff	54
7	Towardin vitro-to-in vivotranslation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms 2017 ·mAbs ·(unknown),Sara Belli,(unknown),Sherri Dudal,(unknown),Markus Haak,(unknown),Michael B. Otteneder,Mohammed Ullah,Christoph Funk,Franz Schuler,(unknown)	18
8	Minipig and Human Metabolism of Aldehyde Oxidase Substrates: In Vitro–In Vivo Comparisons 2017 ·The AAPS Journal ·D. Wilkinson,(unknown),Mingguang Li,Lisa Wright,(unknown),(unknown),(unknown),(unknown),Sarah Johnson,Victoria Shaw,(unknown),(unknown),(unknown),Michael B. Otteneder	13
9	Tissue Distribution of a Therapeutic Monoclonal Antibody Determined by Large Pore Microdialysis 2017 ·Journal of Pharmaceutical Sciences ·Satyawan Jadhav,(unknown),(unknown),Michael B. Otteneder,W. Richter,Hartmut Derendorf	31
10	Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach 2016 ·Pharmaceutical Research ·(unknown),(unknown),Nicole A. Kratochwil,Russell G. Jones,Claudia Suenderhauf,Michael B. Otteneder,Thomas P. Singer,Neil Parrott	17
11	Role of the Intestinal Peptide Transporter PEPT1 in Oseltamivir Absorption: In Vitro and In Vivo Studies 2012 ·Drug Metabolism and Disposition ·Agnès Poirier,Sara Belli,Christoph Funk,Michael B. Otteneder,Renée Portmann,Katja Heinig,Eric Prinssen,Stanley E. Lazic,Craig R. Rayner,Gerhard Hoffmann,Thomas P. Singer,David E. Smith,Franz Schuler	14
12	Discovery of a factor Xa inhibitor (3R,4R)-1-(2,2-difluoro-ethyl)-pyrrolidine-3,4-dicarboxylic acid 3-[(5-chloro-pyridin-2-yl)-amide] 4-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide} as a clinical candidate 2010 ·Bioorganic & Medicinal Chemistry Letters ·Lilli Anselm,David W. Banner,Jörg Benz,Katrin Groebke Zbinden,Jacques Himber,Hans Hilpert,Walter Huber,Bernd Kuhn,Jean‐Luc Mary,Michael B. Otteneder,Narendra Panday,(unknown),Martin Ståhl,(unknown),Wolfgang Haap	31
13	Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: Optimization of in vitro activity 2010 ·Bioorganic & Medicinal Chemistry Letters ·Jens‐Uwe Peters,(unknown),Henrietta Dehmlow,Uwe Grether,(unknown),Dominik Hainzl,Cornelia Hertel,Nicole A. Kratochwil,Michael B. Otteneder,Robert Narquizian,Constantinos G. Panousis,(unknown),Stephan Röver	11
14	Novel Bacterial Acetyl Coenzyme A Carboxylase Inhibitors with Antibiotic Efficacy In Vivo 2006 ·Antimicrobial Agents and Chemotherapy ·Christoph Freiberg,Jens Pohlmann,Peter G. Nell,Rainer Endermann,Joachim Schuhmacher,B. A. Newton,Michael B. Otteneder,Thomas Lampe,(unknown),Karl Ziegelbauer	49
15	Measurement of the malondialdehyde–2′‐deoxyguanosine adduct in human urine by immuno‐extraction and liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry 2004 ·Journal of Mass Spectrometry ·(unknown),Michael B. Otteneder,Lawrence J. Marnett,Henrik E. Poulsen	42
16	Development of a method for determination of the malondialdehyde–deoxyguanosine adduct in urine using liquid chromatography–tandem mass spectrometry 2003 ·Analytical Biochemistry ·Michael B. Otteneder,J. Scott Daniels,Markus Voehler,Lawrence J. Marnett	16
17	DNA adducts of styrene-7,8-oxide in target and non-target organs for tumor induction in rat and mouse after repeated inhalation exposure to styrene 2002 ·Mutation research. Fundamental and molecular mechanisms of mutagenesis ·Michael B. Otteneder,Ursula Lutz,Werner K. Lutz	13
18	Correlation of DNA adduct levels with tumor incidence: carcinogenic potency of DNA adducts 1999 ·Mutation research. Fundamental and molecular mechanisms of mutagenesis ·Michael B. Otteneder,Werner K. Lutz	100
19	³²P-Postlabeling Analysis of DNA Adducts of Styrene 7,8-Oxide at the O⁶-Position of Guanine 1998 ·Chemical Research in Toxicology ·Michael B. Otteneder,Erwin Eder,Werner K. Lutz	16
20	Assessment of the Tumor-Initiating Potential of α,β-Unsaturated Carbonyl Compounds by 32P Postlabeling Quantification of DNA Adducts In Vivo 1997 ·Recent results in cancer research ·Erwin Eder,(unknown),Dirk Schüler,Michael B. Otteneder	3

About Michael B. Otteneder

Michael B. Otteneder is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Cancer Research, having authored 33 papers that have together received 859 indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (10 papers), Protein purification and stability (8 papers) and DNA Repair Mechanisms (6 papers). The work is most often cited by research in Cancer Research (174 citations), Radiology, Nuclear Medicine and Imaging (209 citations) and Chemical Health and Safety (4 citations). Michael B. Otteneder has collaborated with scholars based in Switzerland, United States and Germany. Frequent co-authors include Werner K. Lutz, Lawrence J. Marnett, Sven Kronenberg, Björn Jacobsen, Annika Herrmann, John P. Plastaras, Ben‐Fillippo Krippendorff, James N. Riggins, Hans Peter Grimm and Henrik E. Poulsen. Their work appears in journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Analytical Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact